Successful extracorporeal membrane oxygenation (ECMO) support for fulminant community-acquired pneumococcal pneumonia

Massimiliano Codispoti, Keith Sanger, Pankaj S Mankad

Abstract
A case is described of fulminant community-acquired pneumococcal pneumonia in a 16 year old girl with no previous history of respiratory disease or any predisposing factors. She required extracorporeal membrane oxygenation (ECMO) until the diagnosis could be made and appropriate antibiotic therapy established.

(Thorax 1995;50:1317-1319)

Keywords: pneumococcal pneumonia, extracorporeal membrane oxygenation (ECMO).

Despite advances in antimicrobial therapy, improved diagnostic and microbiological techniques, and sophisticated respiratory support systems,1 pneumonia remains an important cause of mortality and morbidity world wide.2 Rarely, its rapidity of onset may be such that the patient’s condition is severely impaired before appropriate antibiotic therapy can be established. We report the successful use of extracorporeal membrane oxygenation (ECMO) in a girl with community-acquired pneumococcal pneumonia.

Case report
A 16 year old girl presented with a five day history of tiredness, nausea, loss of appetite, and a 24 hour onset of chest ache and yellow sputum. On examination she was pale, tachypnoic, distressed, with a temperature of 37.4°C. There was decreased expansion of the right hemithorax and widespread inspiratory crepitations. Chest radiography showed evidence of consolidation of the right lung and of the mid and lower zones of the left lung (fig 1). White blood count was 2.8 x 10^9/l, platelet count was 133 x 10^9/l. She was found to be negative for HIV, hepatitis B and C. Blood, sputum and urine specimens were sent for culture, together with urine and blood samples for detection of pneumococcal antigen. While awaiting the results, empirical antibiotic/antiviral therapy was established with erythromycin, flucloxacillin, ampicillin, and acyclovir.

A few hours after admission she became increasingly tachypnoic, tachycardic, and hypotensive. Arterial blood gas tensions on 60% FiO2, via a face mask revealed PaO2 of 5-5 kPa and PaCO2 6-23 kPa. She was electively ventilated. While receiving full ventilatory support she became increasingly hypotensive so that it was necessary to start adrenaline and, subsequently, noradrenaline infusion in order to maintain adequate organ perfusion.

The morning after admission, despite maximal inotropic and ventilatory support, the patient’s haemodynamic and ventilatory parameters deteriorated further and were considered incompatible with survival. Therefore, 20 hours after admission she was referred for consideration of ECMO support. The following clinical features were present at the time of referral: heart rate 160 bpm, systemic blood pressure 65/35 mm Hg, central venous pressure 15 mm Hg, pulmonary artery pressure 38/24 mm Hg, cardiac index 5.7/
min/m², systemic vascular resistances 267 dyne·s·cm⁻² with adrenaline 0·5 µg/kg/min, noradrenaline 1·6 µg/kg/min, dopamine 2 µg/kg/min, methoxamine 5·8 µg/kg/min; urinary output of <15 ml/hour; ventilation in continuous mandatory ventilation (CMV) mode, minute volume 13·4 litres, FiO₂ 1·0, positive end expiratory pressure (PEEP) 10 cm H₂O to achieve 65% SaO₂, arterial pH of 7·2, PaO₂ 5·2 kPa, PaCO₂ 8·6 kPa, BE -6, with a calculated intrapulmonary right to left shunt of 66%.

Considering the degree of cardiovascular and respiratory impairment, arteriovenous ECMO was promptly established by percutaneous technique using a centrifugal pump (BioPump, Medtronic Inc, Minneapolis, Minnesota, USA) and a 2·5 m² membrane oxygenator (AVECOR Cardiovascular Ltd, Strathclyde, UK). The pump circuit was primed using 1500 ml of Hartmann’s solution and the haematocrit was maintained at 30–35% during the ECMO support. Arteriovenous cannulation was obtained via a 21 Fr venous cannula and a 17 Fr arterial cannula (DLP Inc, Grand Rapids, Michigan, USA) in the right femoral vein and right femoral artery, respectively. Two hours later, due to impending ischaemia of the right leg, the arterial cannula was removed and reinserted under direct vision in the left femoral artery, together with a 12 Fr cannula (Polystan A/S, Valrose, Denmark) for distal perfusion of the same limb. In order to treat acute renal failure a continuous arteriovenous haemofiltration device was incorporated in the circuit (this was converted into continuous venovenous haemofiltration after discontinuation of ECMO), and rapid improvement of the haemodynamic and ventilatory parameters was obtained. Extracorporeal flow was adjusted with the aim of maintaining the mixed venous oxygen saturation between 65% and 75% and arterial oxygen saturation at >90%. The gas flow of the oxygenator was regulated to maintain a Paco₂ of 5–6 kPa. During ECMO mechanical ventilation was maintained at minimal settings, in CMV mode, minute volume 5 litres, PEEP 5 cm H₂O, FiO₂ 0·3. Intravenous, preservative-free mucus heparin (Pump-Hep, Leo Laboratories Ltd, Princess Risborough, Bucks, UK) was administered at a rate sufficient to maintain the whole blood activated clotting time at 220–250 seconds. During the following 48 hours it was possible to rationalise the antibiotic therapy on the basis of the isolation of an atypical pneumococcus (Streptococcus pneumoniae, type 14) sensitive to erythromycin and benzylpenicillin from the tracheal aspirate; urine and sputum were also positive for pneumococcal capsular antigen. Her respiratory state slowly improved so that by the sixth day of ECMO support this was successfully discontinued. She maintained a PaO₂ of 11 kPa and a PacO₂ of 7·8 kPa while being ventilated in CMV mode, minute volume 8·5 litres, PEEP 6 cm H₂O, FiO₂ 0·8. Her condition continued to improve and on the 15th day she was extubated. Four days later she was transferred to the renal unit and was discharged home 32 days after the end of support with only minimal changes remaining on the chest radiograph (fig 2). She remains symptom-free one year later.

Discussion

Extracorporeal membrane oxygenation in the treatment of adult respiratory failure was virtually abandoned in the United States in 1979 following the publication of disappointing results of the National Institutes of Health (NIH) sponsored multicentre, prospective, randomised trial from 1975 to 1978. These poor results were due to relative inexperience of some of the nine study centres included in the trial, crude coagulation control, the use of venoarterial bypass, and maintenance of the patients on high pressure, high oxygen mechanical ventilation during ECMO. However, continuing efforts by several European centres has led to the revival of adult ECMO, not only in European institutions but also in a few North American centres. The recent experience with adults on ECMO highlights the importance of early intervention in the disease process to achieve a successful outcome. Nevertheless, our patient was moribund with a calculated intrapulmonary left to right shunt of 66% and secondary pump failure. ECMO was offered in desperation as a terminal “rescue attempt”. Venoarterial mode of support was selected despite the recent suggestion favouring a venovenous route in a similar situation. This was due to the extreme type of pathophysiology and to provide better support for the myocardial function. Venovenous access maintains normal pulmonary blood flow in the peripheral lung capillaries, which might thrombose under conditions of low blood flow during venoarterial access. Moreover, microemboli and other embolic material that inevitably form during extra- corporeal circulation are filtered through the pulmonary capillary bed during venovenous bypass; during venoarterial bypass, they are perfused directly into the systemic capillary bed.
Recombinant human DNase in management of lobar atelectasis due to retained secretions

Bsher A Touleimat, Craig S Conoscenti, Jonathan M Fine

Abstract
Recombinant human deoxyribonuclease (rhDNase) is an agent which reduces the viscoelasticity of purulent sputum. Two cases are reported in which rhDNase was utilised for the management of lobar atelectasis due to retained purulent secretions.

Keywords: atelectasis, sputum, recombinant human DNase.

Recombinant human deoxyribonuclease (rhDNase) hydrolyses DNA and has been shown to decrease in vitro the viscoelasticity of sputum from patients with cystic fibrosis. In one study the inhalation of nebulised rhDNase for six days in patients with cystic fibrosis resulted in a 10–20% improvement in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) compared with placebo. In a recent long term study of patients with cystic fibrosis, daily rhDNase administration resulted in a mean improvement in FEV1 of nearly 6%.

Given these encouraging results, we have used rhDNase to clear obstructing sputum in two patients with atelectasis who failed to respond to conventional therapy.

Case 1
A 33 year old man with quadriplegia was admitted with fever, chills, and cough. On physical examination he had a respiratory rate of 24/min and a temperature of 38°C. Chest examination revealed decreased breath sounds. The cardiovascular system, abdomen, and extremities were normal. The admission chest

with potential for multiorgan dysfunction. We feel that these potential problems with a venoarterial circuit can be minimised by maintaining high levels of systemic anticoagulation. The dose of heparin was adjusted to maintain an activated clotting time of 220–250 seconds. Despite this, there were no haematological or bleeding complications in this patient. Heparin-coated circuits and heparin-coated hollow fibre membrane oxygenators have been used for ECMO support. However, the impact of heparin-bonded circuits and heparin-bonded silicone membrane oxygenators (when they become available) on the adult ECMO remains to be determined.

The only ECMO-related complication in our patient was impending ischaemic damage to the limb supplied by the cannulated femoral artery. This was obviated by perfusing the distal femoral artery. For a venoarterial mode of ECMO our protocol now includes distal femoral artery perfusion and cannulation of the femoral artery and vein on different sides. The ventilatory settings whilst on ECMO also make important contributions to the overall outcome, as it is imperative to rest the damaged lung. During the first few days of ECMO support we kept mechanical ventilation to a minimum in order to avoid further lung injury.

We believe that extracorporeal life support techniques should be considered in rapidly progressing acute respiratory failure where (1) diagnosis has not been established but is realistically available within a short time, (2) there is a potentially treatable aetiology, (3) no co-morbid disease likely to adversely affect the outcome is present, and (4) expertise in extracorporeal techniques is available.

Successful extracorporeal membrane oxygenation (ECMO) support for fulminating community-acquired pneumococcal pneumonia.

M Codispoti, K Sanger and P S Mankad

Thorax 1995 50: 1317-1323
doi: 10.1136/thx.50.12.1317

Updated information and services can be found at:
http://thorax.bmj.com/content/50/12/1317

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/